At LSX Congress USA, Form Bio executives argued that investable AI drug discovery increasingly depends on downstream clinical development capabilities—not just faster target identification. The panel highlighted that clinical trials drive most time and cost in medical development, and that cutting discovery timelines has not yet proven higher clinical success rates.